IVA

Inventiva (IVA)

Inventiva

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:EU:IVA

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2025/01/30	06:00	GlobeNewswire Inc.	Inventiva announces the publication of the results from the investigator-initiated proof-of-concept clinical trial evaluating lanifibranor in patients with T2D and MASLD in the Journal of Hepatology	EU:IVA	Inventiva
2025/01/25	06:00	GlobeNewswire Inc.	Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux	EU:IVA	Inventiva
2025/01/23	06:00	GlobeNewswire Inc.	Results of LEGEND evaluating lanifibranor in combination with empagliflozin in MASH selected for oral presentation at the upcoming EASL SLD Summit 2025	EU:IVA	Inventiva
2024/12/18	06:00	GlobeNewswire Inc.	Inventiva to present at the 43rd Annual J.P. Morgan Healthcare Conference	EU:IVA	Inventiva
2024/12/16	16:30	GlobeNewswire Inc.	Inventiva secures €21.4 million and completes the first tranche of the previously announced multi-tranche financing of up to €348 million	EU:IVA	Inventiva
2024/12/13	06:00	GlobeNewswire Inc.	Results of the votes of the Combined Shareholders’ General Meeting of December 11, 2024	EU:IVA	Inventiva
2024/11/22	06:00	GlobeNewswire Inc.	Inventiva reports 2024 Third Quarter Financial Information¹	EU:IVA	Inventiva
2024/11/21	06:00	GlobeNewswire Inc.	Combined General Meeting of December 11, 2024 - Availability of the preparatory documents	EU:IVA	Inventiva
2024/11/16	06:00	GlobeNewswire Inc.	Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® late-breaker session	EU:IVA	Inventiva
2024/10/31	05:00	GlobeNewswire Inc.	Inventiva announces the positive recommendation of the fifth DMC of the NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASH	EU:IVA	Inventiva
2024/10/21	21:30	GlobeNewswire Inc.	Inventiva announces a late breaker abstract from LEGEND, Phase 2 trial, evaluating lanifibranor in combination with empagliflozin in MASH at the AASLD The Liver Meeting® 2024	EU:IVA	Inventiva
2024/10/15	02:45	GlobeNewswire Inc.	Inventiva announces the availability of a prospectus in connection with its financing through the issuance of ordinary shares and pre-funded warrants	EU:IVA	Inventiva
2024/10/14	15:35	GlobeNewswire Inc.	Inventiva announces Filing of 2024 Half-Year Report – Conditions for Accessing or Consulting the Report	EU:IVA	Inventiva
2024/10/14	15:30	GlobeNewswire Inc.	Inventiva announces financing of up to €348 million to advance the NATiV3 Phase 3 MASH study	EU:IVA	Inventiva
2024/09/26	05:00	GlobeNewswire Inc.	Inventiva provides a corporate update and reports its unaudited 2024 first-half financial results	EU:IVA	Inventiva
2024/08/01	05:00	GlobeNewswire Inc.	Inventiva Reports Preliminary 2024 First-Half Financial Information¹	EU:IVA	Inventiva
2024/07/26	05:00	GlobeNewswire Inc.	Inventiva secures a new patent in Japan, expanding the IP protection of its lead product candidate lanifibranor	EU:IVA	Inventiva
2024/07/18	15:30	GlobeNewswire Inc.	Inventiva announces a €20.1 million issuance of royalty certificates	EU:IVA	Inventiva
2024/07/06	05:00	GlobeNewswire Inc.	Inventiva provides an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH and its financial position	EU:IVA	Inventiva
2024/07/06	05:00	GlobeNewswire Inc.	Inventiva fait le point sur son programme clinique NATiV3 évaluant lanifibranor dans la MASH/NASH et sur sa situation financièr	EU:IVA	Inventiva
2024/07/06	05:00	GlobeNewswire Inc.	Inventiva provides an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH and its financial position	EU:IVA	Inventiva
2024/06/22	05:05	GlobeNewswire Inc.	Description of the Share Repurchase Program Authorised by the Ordinary General Meeting of 20 June 2024	EU:IVA	Inventiva
2024/06/22	05:05	GlobeNewswire Inc.	DESCRIPTIF DU PROGRAMME DE RACHAT D’ACTIONS AUTORISE PAR L'ASSEMBLEE GENERALE ORDINAIRE DU 20 JUIN 2024	EU:IVA	Inventiva
2024/06/22	05:05	GlobeNewswire Inc.	Description of the Share Repurchase Program Authorised by the Ordinary General Meeting of 20 June 2024	EU:IVA	Inventiva
2024/06/22	05:00	GlobeNewswire Inc.	Results of the votes of the Combined Shareholders’ General Meeting of June 20, 2024	EU:IVA	Inventiva
2024/06/22	05:00	GlobeNewswire Inc.	Résultats des votes de l’Assemblée Générale Mixte des actionnaires réunies le 20 juin 2024	EU:IVA	Inventiva
2024/06/22	05:00	GlobeNewswire Inc.	Results of the votes of the Combined Shareholders’ General Meeting of June 20, 2024	EU:IVA	Inventiva
2024/05/30	15:30	GlobeNewswire Inc.	Assemblée Générale Mixte du 20 juin 2024 - Modalités de mise à disposition des documents préparatoires	EU:IVA	Inventiva
2024/05/30	15:30	GlobeNewswire Inc.	Combined General Meeting of June 20, 2024 - Availability of the preparatory documents	EU:IVA	Inventiva
2024/05/30	15:30	GlobeNewswire Inc.	Statement of total voting rights and shares forming the company’s share capital as of May 13, 2024	EU:IVA	Inventiva